Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
It has been shown that NMDA receptor antagonists can inhibit both the development and expression of a decrease in the duration of L-DOPA action in rats rotating after unilateral lesion of the nigro-striatal dopaminergic system. Using this model we found that the low affinity NMDA receptor antagonist amantadine (50 mg/kg b.i.d.) attenuated both the expression and development of the shortening of duration of L-DOPA (25 mg/kg b.i.d.) action. Amantadine was most efficient when given both during the induction and expression phase. However, an additional interaction experiment demonstrated that acutely given amantadine also prolongs the duration of L-DOPA-induced rotations. Hence, only the effect on development of shortening of L-DOPA action can be regarded as specific for repetitive treatment mode. The data suggest that treatment with amantadine might have beneficial effects on response fluctuations produced by chronic L-DOPA treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s007020050125 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!